ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag gene patents genetics genomics immunology

Bugs as Drugs to Boost Cancer Therapy
Danielle Gerhard, PhD | Jan 18, 2024 | 7 min read
Bioengineered bacteria sneak past solid tumor defenses to guide CAR T cells’ attacks.
Controversy Mounts Over Gene Patenting Policy
Scott Veggeberg | Apr 26, 1992 | 5 min read
Scientists in industry and academia foresee trouble as NIH persists in claiming ownership over partial sequences Date: April 27, 1992 The reviews from the scientific community remain mostly negative over the National Institutes of Health's patent application for a total of 2,722 partial human gene sequences. Academic researchers, who say they are mostly unaffected by the patenting process, nevertheless are appalled; and while some in the commercial sector of the biotech community now believe
Will Genomics Spoil Gene Ownership?
Douglas Steinberg | Sep 3, 2000 | 8 min read
Consider a scenario for the year 2002: Using commercially available software, bioprospector "Craig Collins" spends a day scavenging the Human Genome Project (HGP) database for the alternatively spliced genes prized by Wall Street. He enters the sequences of several candidate genes into a software package that prints out the likely functions of their protein products. One protein looks like it could be pharmaceutical paydirt, so he isolates the corresponding cDNA, inserts it into a vector, then
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard
Philip Leder, Who Deciphered Amino Acid Sequences, Dies
Ashley Yeager | Feb 12, 2020 | 4 min read
The Harvard Medical School researcher’s work on the genetic basis of protein coding and production led him to make groundbreaking discoveries in immunology, molecular biology, and cancer genetics.
Gene Patenting Is On The Rise, But Scientists Are Unimpressed
Franklin Hoke | Apr 16, 1995 | 8 min read
Buoyed by enabling legislation and scientific advances, institutions are aggressively shopping their faculties' `blue-sky' investigations. In just the past year, patents on the genes implicated in obesity, breast cancer, and other disorders have generated headlines in newspapers across the United States. In several of these cases, scientists have turned their patented discoveries into lucrative commercial deals worth several times their funding from other sources--crucial money in light of pro
Going Viral
Breeann Kirby and Jeremy J. Barr | Sep 1, 2013 | 10+ min read
From therapeutics to gene transfer, bacteriophages offer a sustainable and powerful method of controlling microbes.
Spraying spray bottle
Nasal Vaccines Are Commercially High Risk, Perhaps High Reward
Jef Akst | Jun 13, 2022 | 10+ min read
Dozens of intranasally delivered vaccines targeting SARS-CoV-2 are in development. Could they pave the way for widespread nasal vaccination in the future?
HHS Secretary Sullivan To Determine If NIH Gene Patent Quest Is Over
Scott Veggeberg | Oct 25, 1992 | 6 min read
The decision on whether the National Institutes of Health should continue its quest for patents on partial human cDNA sequences now rests with Health and Human Services secretary Louis Sullivan. In September, NIH director Bernadine Healy revealed that the agency had received an initial rejection from the United States Patent and Trademark Office (PTO) for the approximately 2,700 partial gene sequences generated by former NIH researcher Craig Venter and others. Then, on October 5, an HHS spok
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.

Run a Search

ADVERTISEMENT